{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-103254","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.491677+00:00","generated_at":"2026-05-17T01:55:00.755245+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Annovis Bio raises ~$3.4M in offering of 1.67M shares at $2.05 for Alzheimer's trial","bullets":["1,670,732 shares at $2.05 each; gross proceeds ~$3.425M before expenses.","Two board members purchase 1,073,171 shares under separate subscription agreements.","Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.","Placement agent H.C. Wainwright receives 7% cash fee and warrants for 83,537 shares at $2.5625.","Closing expected October 28, 2025; lock-up on further issuance until November 28, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-103254","json":"https://secwatch.observer/filing/0001104659-25-103254.json","markdown":"https://secwatch.observer/filing/0001104659-25-103254.md","text":"https://secwatch.observer/filing/0001104659-25-103254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/0001104659-25-103254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/tm2529544d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:55:00.755245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}